U.S. biotech pharmaceutical firm

U.S. biotech firm Celgene to buy Impact Biomedicines for up to USD 7 billion

U.S. biotech firm Celgene to buy Impact Biomedicines for up to USD 7 billion

From our online archive

08 Jan 2018

1 min read

The New Indian Express

www.newindianexpress.com